Национальный цифровой ресурс Руконт - межотраслевая электронная библиотека (ЭБС) на базе технологии Контекстум (всего произведений: 634932)
Контекстум
Руконтекст антиплагиат система

Молекулярная иммунопатология рака мочевого пузыря (822,57 руб.)

0   0
Доступно в Google Play
Первый авторLi Chong
ИздательствоТяньцзиньская научно-техническая пресса
Страниц186
822,57р Предпросмотр
ID718571
АннотацияМолекулярная Иммунопатология рака мочевого пузыря разделена на 89 глав, посвященных функциям 89 генов, связанных с раком мочевого пузыря, и их экспрессии в тканях рака мочевого пузыря, включая многие горячие точки рака мочевого пузыря. Эта книга полна содержания, богата диаграммами и проста в использовании. Это незаменимый инструмент в области онкологии. Он подходит для старших магистрантов и аспирантов в области биохимии и молекулярной биологии, клеточной биологии и других смежных специальностей. Она также может быть использован в качестве учебного пособия для преподавателей и как научный справочник, а также понятен для исследователей в области биомедицины, фармакологии, иммунологии и смежных областях. < / p>
ISBN978-7-5576-5785-7
Li, C. Молекулярная иммунопатология рака мочевого пузыря / C. Li .— : Тяньцзиньская научно-техническая пресса, 2019 .— 186 с. — ISBN 978-7-5576-5785-7 .— URL: https://rucont.ru/efd/718571 (дата обращения: 28.04.2024)

Предпросмотр (выдержки из произведения)

Молекулярная_иммунопатология_рака_мочевого_пузыря.pdf
内容简介 《膀胱癌分子免疫病理》共分89章，重点阐述了膀胱癌相关的89个基因的功能及在 膀胱癌组织中的表达情况，涉及众多膀胱癌热点基因。本书内容充实、图表丰富、使用 方便，是肿瘤学领域不可或缺的工具用书，适用于生物化学与分子生物学、细胞生物学 等相关专业的高年级本科生、研究生，也可作为教师的教学和科研参考书，亦可供生物 医学、药理学、免疫学及相关领域的研究人员参考。 膀胱癌分子免疫病理 / 李翀主编 . -- 天津 : 天津 科学技术出版社, 2019.1 ISBN 978-7-5576-5785-7 Ⅰ. ①膀… Ⅱ. ①李… Ⅲ.①膀胱癌-分子免疫-病 理学 Ⅳ. ①R737.140.2 230345 膀胱癌分子免疫病理 PANGGUANGAI FENZI MIANYI BINGLI 孟祥刚 23332695 天津午阳印刷股份有限公司 定价：78.00 元 2019 年 1 月第 1 版第 1 次印刷 787×1092 1/16 11.75 200 000
Стр.3
主 编 李 翀 副主编 杨 昭 颜汝平 编 委 （按姓氏笔画排序） 王建华 王美青 王海峰 朱学加 张 旭 李 翀 李 义 祝焕新 杨 昭 秦怡璠 康 星 黄力耘 楚红蕾 谭 雪 颜汝平
Стр.4
ABCB1········································································································1 ABCC1········································································································3 ABCG2········································································································5 ABL1··········································································································7 AKT1··········································································································9 AKT2········································································································ 11 APC ········································································································· 13 ARID1A ···································································································· 15 ATM ········································································································· 17 AURKA····································································································· 19 B2M ········································································································· 21 BCL2 ········································································································ 23 BIRC5······································································································· 25 CASP8 ······································································································ 27 CCND1······································································································ 29 CD74 ········································································································ 31 CD79A ······································································································ 33 CDH1········································································································ 35 CDK1········································································································ 37 CDK2········································································································ 39 CDK4········································································································ 41 CDKN1B ··································································································· 43 CDKN2A ··································································································· 45 CREBBP ···································································································· 47 CTNNB1···································································································· 49 CYP1A1 ···································································································· 51 CYP1A2 ···································································································· 53 CYP1B1····································································································· 55 CYP2D6 ···································································································· 57 ·1·
Стр.5
膀胱癌分子免疫病理 CYP2E1····································································································· 59 E2F1········································································································· 61 EGFR········································································································ 63 EP300 ······································································································· 65 ERBB2 ······································································································ 67 ERBB3 ······································································································ 69 ERBB4 ······································································································ 71 ERCC1 ······································································································ 73 ERCC2 ······································································································ 75 EZH2 ········································································································ 77 FBXW7 ····································································································· 79 FGFR3 ······································································································ 81 GATA3 ······································································································ 83 GSTM1······································································································ 85 GSTP1······································································································· 87 GSTT1 ······································································································ 89 HGF ········································································································· 91 HIF1A······································································································· 93 HRAS ······································································································· 95 HSP90AA1 ································································································· 97 IGF1R ······································································································· 99 IGF2 ········································································································ 101 JUN········································································································· 103 KDM6A····································································································105 KMT2A ····································································································107 KMT2D ····································································································109 KRAS ······································································································ 111 MAPK1 ···································································································· 113 MAPK14··································································································· 115 MAPK8 ···································································································· 117 MDM2 ·····································································································119 MET ········································································································ 121 MTOR······································································································ 123 MYC········································································································ 125 NAT1 ······································································································· 127 NAT2 ······································································································· 129 NCOR1·····································································································131 ·2·
Стр.6
目 录 NFKBIA ··································································································· 133 NOS3······································································································· 135 PARP1······································································································ 137 PIK3CA ···································································································· 139 PPARD ····································································································· 141 PTEN······································································································· 143 RB1·········································································································145 ROS1 ······································································································· 147 SOD2······································································································· 149 SOX2······································································································· 151 SOX9······································································································· 153 SRC········································································································· 155 STAG2 ····································································································· 157 STAT1 ······································································································ 159 STAT3 ······································································································ 161 SULT1A1 ·································································································· 163 TGFBR1 ··································································································· 165 TP53········································································································ 167 TYMS ······································································································ 169 VEGFA····································································································· 171 XPC ········································································································ 173 XRCC1·····································································································175 XRCC4·····································································································177 ·3·
Стр.7

Облако ключевых слов *

* - вычисляется автоматически
Антиплагиат система на базе ИИ